Hugh Davis, PhD
CHIEF OPERATING OFFICER & PRESIDENT, BIOSION USA, INC., BIOSION, INC.
Newark, Delaware, United States
Dr. Davis is currently Chief Operating Officer & President of Biosion USA, Inc, where he is responsible for preclinical and clinical development of innovative biologic therapies in Biosion’s pipeline. He is also responsible for Business Development including licensing, partnerships and investments. Dr. Davis has over 30 years of experience in the biotech and pharmaceutical industries. He joined Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer, leading the company to a very successful IPO in 2019. Prior to Frontage, Dr. Davis worked with Johnson & Johnson where he served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. During his tenure in J&J, Hugh and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Darzalex® and Tremfya®. Hugh received his Ph.D. from Villanova University.